The same blue food dye found in M&Ms and Gatorade could be used to reduce damage caused by spine injuries, offering a better chance of recovery, according to new research.
Researchers at the University of Rochester Medical Center found that when they injected the compound Brilliant Blue G (BBG) into rats suffering spinal cord injuries, the rodents were able to walk again, albeit with a limp. The only side effect was that the treated mice temporarily turned blue. The results of the study, published in the “Proceedings of the National Academy of Sciences,” build on research conducted by the same center five years ago. In August 2004, scientists revealed how Adenosine triphosphate, which is known as ATP and described as the “energy currency of life,” surges to the spinal cord soon after injury occurs. Researchers found that the sudden influx of ATP killed off healthy cells, making the initial injury far worse. But when they injected oxidized ATP into the injury, it was found to block the effect of ATP, allowing the injured rats to recover and walk again. “While we achieved great results when oxidized ATP was injected directly into the spinal cord, this method would not be practical for use with spinal cord-injured patients,” said lead researcher Maiken Nedergaard, professor of Neurosurgery and director of the Center for Translational Neuromedicine at the University of Rochester Medical Center. “First, no one wants to put a needle into a spinal cord that has just been severely injured, so we knew we needed to find another way to quickly deliver an agent that would stop ATP from killing healthy motor neurons. Second, the compound we initially used, oxidized ATP, cannot be injected into the bloodstream because of its dangerous side effects.”
Don’t Miss
Guidelines for broader stem cell research unveiled
Stem cell transplant ‘very encouraging’ for type 1 diabetes
A primer on stem cells
Back in 2004, Nedergaard’s team discovered that the spinal cord was rich in a molecule called P2X7, which is also known as “the death receptor” for its ability to allow ATP to latch onto motor neurons and send the signals which eventually kill them. Nedergaard knew that BBG could thwart the function of P2X7, and its similarity to a blue food dye approved by the Food and Drug Administration in 1982 gave her the confidence to test it intravenously. It worked. The rats given BBG immediately after their injury could walk again with a limp. Those that didn’t receive a dose never regained their mobility. Researchers say it could be several years before their findings lead to a practical application for BBG in humans. They also stress the treatment is designed to reduce the secondary damage that is caused immediately after the injury. “Our hope is that this work will lead to a practical, safe agent that can be given to patients shortly after injury, for the purpose of decreasing the secondary damage that we have to otherwise expect,” said Steven Goldman, Chair of the University of Rochester Department of Neurology. The researchers say more testing is needed to assess the safety of BBG before human clinical trials could begin.
